WallSt.net (www.wallst.net ) Updates the Investment Community Through All-New Interviews with BPA, PPCO and NVAX
10 July 2007 - 9:00PM
PR Newswire (US)
NEW YORK, July 10 /PRNewswire/ -- On June 19, Stephen Simes, CEO of
Biosante Pharmaceuticals, Inc. (AMEX:BPA)
(http://www.biosantepharma.com/ ) updated the investment community
in an all-new interview with http://www.wallst.net/. Interview
highlights include detailed discussions on the following topics: --
the company's "wide portfolio" of hormone therapy products -- size
of the company's target markets, and market opportunities for the
company's gel formulations -- hormone therapy products in
development -- reasons the company's transdermal products have a
competitive edge -- upcoming milestones for investors to watch for
To hear the interview in its entirety, and to read an in-depth
report on the company, visit
http://www.wallst.net/superstocks/superstocks_profile.asp?ticker=bpa
On June 29, Jennifer Good, President CEO of Penwest Pharmaceuticals
Co. (NASDAQ:PPCO) (http://www.penw.com/) updated the investment
community in an all-new interview with http://www.wallst.net/.
Interview highlights include detailed discussions on the following
topics: -- reasons the company is going through a "bit of a
transition" -- why Opana ER "has a lot of earnings leverage for
Penwest" -- the company's relationship with Endo Pharmaceuticals,
Inc. -- the company's three-pronged strategy to build its pipeline
-- building a specialty sales force in neurology -- industry trends
bolstering the company's growth prospects -- upcoming milestones
for investors to watch for To hear the interview in its entirety,
visit http://www.wallst.net/audio/audio.asp?ticker=PPCO&id=3565
On June 20, Dr. Rahul Singhvi, President and CEO of Novavax, Inc.
(NASDAQ:NVAX) (http://www.novavax.com/ ) updated the investment
community in an all-new interview with http://www.wallst.net/.
Interview highlights include detailed discussions on the following
topics: -- reasons the company is "very well positioned to be a
major vaccine player" -- commercial opportunities for the company's
virus-like-particle approach to vaccine development -- initial
targets for vaccine development -- development of the company's
Avian Flu vaccine candidate -- proven track record of
virus-like-particle-based drugs -- upcoming development milestones
for investors to watch for To hear the interview in its entirety,
and to read an in-depth article on the company, visit
http://www.wallst.net/editorials/article.asp?id=731 About
WallSt.net: http://www.wallst.net/ is owned and operated by
WallStreet Direct, Inc., a wholly owned subsidiary of Financial
Media Group, Inc. (http://www.financialmediagroupinc.com/). The Web
site is a leading provider of timely business news, executive
interviews, multimedia content, and research tools. Financial Media
Group, Inc. also owns http://www.mywallst.net/, a financial social
network for investors, and Financial Filings Corp.
(http://www.financialfilings.com/), a provider of media and
compliance solutions to publicly traded companies. In addition to
WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio
(http://www.wallstradio.com/), a business and finance podcast Web
site. We have received nine thousand nine hundred ninety five
dollars from Biosante Pharmaceuticals, Inc. for media and
advertising services. For a complete list of our advertisers, and
advertising relationships, visit
http://www.wallst.net/disclaimer/disclaimer.asp . (Logo:
http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)
http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO
http://photoarchive.ap.org/ DATASOURCE: WallStreet Direct, Inc.
CONTACT: Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALLST
Web site: http://www.biosantepharma.com/ http://www.wallst.net/
http://www.penw.com/ http://www.novavax.com/
Copyright
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Biosante Pharmaceuticals (American Stock Exchange): 0 recent articles
More Biosante Pharmaceuticals, News Articles